Registration Opening Soon for BOS Events 2025!

Dates for BOS Events 2025 are confirmed as 11th and 12th June for BOS Basel 2025 and 25th and 26th November for BOS Manchester 2025. Please find further details outlining provisional floor plans and pricing options at the event links provided. Note that we plan to open for registrations on Monday 4th November at 09.00 GMT.

The focus of these events is partnerships in R&D outsourcing with the primary scope being development-stage CMC outsourcing of Small Molecules, Biologics and New Therapeutic Entities.

We continue to evaluate the opportunity for digital events and resources, please look out for an announcement soon on this. We look forward to welcoming you and your colleagues to BOS Events! Please contact the Bio2Business team for further details.

Featured Company (BOS Manchester 2024)

M3 Pharma Consultancy
M3 Pharma Consultancy is a Dutch consultancy company dedicated to support the development of new medicinal products. Support can be provided at any stage, e.g. from defining phase-appropriate CMC strategies for pharma/biotech clients to coordinating their outsourced activities at CDMO/CRO’s. With a...
View profile

Featured Speaker (BOS Manchester 2024)

Early Chemical Development and Optimization of A Novel Macrocyclic PKC Theta Inhibitor

Dr Craig Harris, Founder and CEO, CMC Innov

ABSTRACT: The link between psoriasis and protein kinase C theta (PKCθ) inhibition lies in the role PKCθ plays in the immune response, particularly in T cell activation and inflammation, which are central to psoriasis pathogenesis. PKC Theta was Galderma’s first oral medchem project and probably the most challenging of the three small molecule projects we transferred from our R&D facility in Sophia-Antipolis, France, to our offices in Switzerland to be ran in a fully outsourced manner. This talk will focus upon the CMC challenges we encountered during the transfer and scale-up of our development candidate... Click here to Read More